NSCLC

This study is exploring if a simple blood test, called a liquid biopsy, can help doctors monitor how well the drug brigatinib is working for patients with a specific type of advanced non-small cell lung cancer. The drug is taken daily to control the cancer. The research aims to s…

This study is testing whether a new experimental drug called AK112, which targets two pathways involved in cancer growth, works better when combined with standard chemotherapy for advanced non-small cell lung cancer (NSCLC). It will involve about 265 adults with stage IIIB/C or I…

This study is testing the drug lazertinib as the first treatment for people with advanced non-small cell lung cancer that has specific EGFR mutations. Researchers want to see how well the drug works, how safe it is, and understand why some patients' cancers eventually stop respon…

This study is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy after lung cancer surgery can better prevent the cancer from returning. It is for patients who have had surgery for certain stages of non-small cell lung cancer and still have traces…

This is an early-stage study testing the safety and initial effectiveness of a new drug called CLN-619. It is being given to adults with advanced solid tumors that have spread or cannot be removed by surgery. Researchers are testing CLN-619 by itself and combined with other appro…

This study provides continued access to the lung cancer drug lorlatinib for patients who are already benefiting from it in previous Pfizer studies. It allows 76 participants with ALK-positive or ROS1-positive non-small cell lung cancer to keep receiving treatment while researcher…

This study aimed to find the best timing for using a newer lung cancer drug called osimertinib in patients with a specific genetic change (EGFR mutation). It compared starting the drug right away versus starting an older drug first and then switching to osimertinib later, guided …

This study aims to find out if it's safe and effective for people with a specific type of advanced lung cancer (EGFR-positive NSCLC) to continue taking their daily oral medication, osimertinib, while also receiving radiation therapy. It involves 42 participants who need radiation…

This study is testing whether adding very high doses of vitamin C (given through an IV) to standard chemotherapy and radiation treatment helps people with non-small cell lung cancer. All 43 participants will receive the vitamin C infusion along with their usual cancer therapy. Re…

This study is testing whether adding a new immunotherapy drug called cadonilimab (AK104) to standard chemotherapy and radiation can better control advanced, inoperable lung cancer. It involves 41 patients who will receive the drug before, during, and for a year after their standa…

This study is testing an oral medication called BDTX-1535 for adults with advanced non-small cell lung cancer or glioblastoma (a type of brain tumor) that have specific genetic changes. The goal is to find the safest and most effective dose and see if the drug can shrink tumors, …

This study is testing two different immunotherapy drug combinations, given before and after standard chemoradiation, for people with stage III non-small cell lung cancer that cannot be removed by surgery. The goal is to see which combination is more promising for keeping the canc…

This study is testing whether adding an immunotherapy drug called durvalumab to a precise form of radiation therapy (SBRT) works better than radiation alone for early-stage lung cancer. It is for patients with a higher risk of their cancer returning who are not candidates for sur…

This study provides continued access to crizotinib treatment for people with certain cancers who were already benefiting from the medication in previous Pfizer trials that are closing. It allows 27 eligible participants to keep receiving their treatment while researchers continue…

This early-stage study is testing a drug called furmonertinib for people with advanced non-small cell lung cancer that has a specific genetic mutation called EGFR exon 20 insertion. The trial will enroll 30 people to see if the drug is safe and can help shrink or control their tu…

This early-phase study is testing an experimental oral medication called MRT-2359 in people with advanced cancers that have run out of standard treatment options. The trial focuses on several types of solid tumors and lymphoma, particularly those driven by specific genes called L…

This study is testing whether adding an immunotherapy drug called serplulimab to standard chemotherapy before surgery helps people with operable non-small cell lung cancer. The goal is to see if this combination treatment can better shrink tumors before removal, lower the chance …

This study is testing an experimental drug called JAB-21822 (glecirasib) for people with advanced cancers that have a specific genetic change called KRAS G12C mutation. The trial aims to find the safest and most effective dose while checking if the drug can shrink tumors. It incl…

This study aims to see if the drug brigatinib works better than other similar drugs for people with a specific type of advanced lung cancer (ALK-positive NSCLC). It will involve about 118 adults who have not yet received treatment for their advanced cancer. Researchers will close…

This study is testing whether combining a drug called durvalumab (an immunotherapy) with radiation therapy can help control locally advanced non-small cell lung cancer. It is for patients who are not eligible for the standard treatment of chemotherapy followed by radiation, often…

This study is testing whether adding a drug called S-1 to a standard lung cancer medication (osimertinib) can help control cancer that has started growing again. It is for 30 adults with a specific type of advanced lung cancer (EGFR mutant NSCLC) that has become resistant to osim…

This early-stage trial is testing the safety and best dose of a new two-drug combination for people with advanced solid tumors that have stopped responding to standard treatments. The study is focusing on specific cancers, including certain types of lung, ovarian, and pancreatic …

This large, global study is comparing a new three-drug combination to the current standard treatment for adults with advanced non-small cell lung cancer (NSCLC) that has spread and lacks certain genetic markers. The goal is to see if the new combination, which includes an experim…

This early-stage trial is testing the safety and finding the right dose of a two-drug combination (naptumomab estafenatox and durvalumab) for people with advanced or metastatic solid tumors. It will enroll about 120 adults with one of many eligible cancer types, including breast,…

This study aimed to see if a new drug called poziotinib works better than standard chemotherapy (docetaxel) for people with advanced non-small cell lung cancer that has a specific HER2 gene mutation and has worsened after prior treatments. It directly compared how long each treat…

This study is testing whether new drug treatments given before surgery can shrink lung tumors and prevent cancer from coming back. It's for people with early-stage non-small cell lung cancer that can be surgically removed. Researchers are looking at how patients' specific cancer …

This study is testing an oral drug called furmonertinib for adults with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion) and has worsened after standard chemotherapy. The main goal is to see if the drug can shrink tumors and control …

This study is testing whether using a precise, high-dose radiation treatment on a few new or growing tumors can help people with advanced lung or breast cancer stay on their current medications longer. It aims to see if this approach can delay the cancer from getting worse. The t…

This is a research study trying to understand what might cause lung cancer in people under age 50. Participants who already have lung cancer complete online surveys and may donate a blood sample from home. The goal is to learn if lifestyle, environment, or genetics play a role in…

This study observes 800 patients with a specific type of advanced lung cancer (ALK-positive NSCLC) who are already receiving the drug alectinib as part of their regular medical care. Researchers will track how long patients benefit from the treatment, what happens when they need …

This study aims to see if a simple blood test can predict whether lung cancer will return after surgery. Researchers will test blood from patients before and after their lung cancer operation, looking for tiny DNA fragments from the tumor. The goal is to see if the test results o…